ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Davisite
|
272 |
83K |
8 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
272
|
83K
|
8
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Davisite
|
272 |
83K |
2 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
272
|
83K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
7 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
821
|
205K
|
7
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Results of Rights Issue Offer
|
|
Davisite
|
21 |
4.1K |
10 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
21
|
4.1K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Davisite
|
549 |
169K |
7 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
549
|
169K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
DrT the GOAT
|
|
Davisite
|
1 |
909 |
12 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
1
|
909
|
12
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
88 |
18/03/24 |
18/03/24 |
General
|
10K
|
3.7M
|
88
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene shows potent anticancer activity in AML models
|
|
Davisite
|
87 |
31K |
26 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
87
|
31K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
7 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
821
|
205K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Chief Financial Officer Appointment
|
|
Davisite
|
9 |
2.9K |
35 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
9
|
2.9K
|
35
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Davisite
|
20K |
6.9M |
82 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
20K
|
6.9M
|
82
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to multi-dose
|
|
Davisite
|
33 |
8.2K |
13 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
33
|
8.2K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to multi-dose
|
|
Davisite
|
33 |
8.2K |
5 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
33
|
8.2K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to multi-dose
|
|
Davisite
|
33 |
8.2K |
22 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
33
|
8.2K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Professor Erin Howden Joins Race Oncology SAB
|
|
Davisite
|
22 |
9.1K |
30 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
22
|
9.1K
|
30
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Davisite
|
20K |
6.9M |
48 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
20K
|
6.9M
|
48
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
43 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
821
|
205K
|
43
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to multi-dose
|
|
Davisite
|
33 |
8.2K |
21 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
33
|
8.2K
|
21
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
Davisite
|
20K |
6.9M |
32 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
20K
|
6.9M
|
32
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to multi-dose
|
|
Davisite
|
33 |
8.2K |
22 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
33
|
8.2K
|
22
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Theranostic prostate cancer trial advances to multi-dose
|
|
Davisite
|
33 |
8.2K |
32 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
33
|
8.2K
|
32
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
1 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
821
|
205K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
10 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
821
|
205K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Professor Erin Howden Joins Race Oncology SAB
|
|
Davisite
|
22 |
9.1K |
170 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
22
|
9.1K
|
170
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Appendix 4D & Half-Year Financial Statements
|
|
Davisite
|
57 |
13K |
31 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
57
|
13K
|
31
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
33 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
33
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
38 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
38
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
21 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
21
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
12 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
12
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
5 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
5
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
28 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
28
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
10 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
10
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
10K |
3.7M |
10 |
13/03/24 |
13/03/24 |
General
|
10K
|
3.7M
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
12 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
821
|
205K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
37 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
821
|
205K
|
37
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
821
|
205K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
5 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
821
|
205K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
821
|
205K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
821
|
205K
|
0
|
|
ASX - By Stock
|
IDA |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
Davisite
|
16 |
6.5K |
7 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
16
|
6.5K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Davisite
|
279 |
83K |
26 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
279
|
83K
|
26
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Davisite
|
279 |
83K |
26 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
279
|
83K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
Davisite
|
821 |
205K |
20 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
821
|
205K
|
20
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Davisite
|
279 |
83K |
11 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
279
|
83K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Davisite
|
279 |
83K |
14 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
279
|
83K
|
14
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Davisite
|
279 |
83K |
15 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
279
|
83K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene shows potent anticancer activity in AML models
|
|
Davisite
|
87 |
31K |
18 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
87
|
31K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene shows potent anticancer activity in AML models
|
|
Davisite
|
87 |
31K |
13 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
87
|
31K
|
13
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Davisite
|
279 |
83K |
6 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
279
|
83K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Davisite
|
549 |
169K |
5 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
169K
|
5
|
|